Alebund Pharmaceuticals Initiates Global Phase IIb Trial of AP306, First-in-Class Oral Pan-Phosphate Transporter Inhibitor for Hyperphosphatemia
Alebund Pharmaceuticals (HKG: 9637) announced that the first patient has been randomized and dosed in...
Alebund Pharmaceuticals
Alebund Pharmaceuticals Raises $163M in Hong Kong IPO to Advance Kidney Disease Pipeline
Alebund Pharmaceuticals (Jiangsu) Limited (HKG: 9637) successfully completed its initial public offering (IPO) on the...
Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
Alebund Pharmaceuticals, a Shanghai-based biopharmaceutical company focused on kidney disease therapeutics, has filed its prospectus...
Alebund Pharma Licenses AP306 to R1 Therapeutics – USD 100 Million Deal for First‑in‑Class Hyperphosphatemia Drug
Alebund Pharmaceuticals has entered into an exclusive licensing agreement with R1 Therapeutics, Inc. (UK) for...
Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines
Shanghai-based Alebund Pharmaceuticals has announced the completion of a Series C financing round, raising RMB...
Alebund Pharmaceuticals’ AP306 Earns Breakthrough Designation for Chronic Kidney Disease
Alebund Pharmaceuticals, based in Shanghai, has announced that its drug candidate AP306 (EOS789), a pan-inhibitor...
Alebund Pharmaceuticals Secures Exclusive Rights to Roche’s Mircera in China
Shanghai-based Alebund Pharmaceuticals has entered into a commercialization agreement with Swiss pharmaceutical giant Roche (SWX:...
Alebund Pharmaceuticals Secures $29M in Pre-Series C Funding and $116M Loan for R&D and Manufacturing
Shanghai-based Alebund Pharmaceuticals has announced the completion of a pre-Series C financing round worth RMB...